[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646198":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":42,"collaborators":20,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":20,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Eidos Therapeutics, a BridgeBio company","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Acoramidis (AG10)","EXPERIMENTAL","Open-label study where all participants will receive acoramidis (AG10) during the study",[13],"Drug: Acoramidis (AG10) oral tablet",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Acoramidis (AG10) oral tablet","Study drug is defined as acoramidis 712 mg (equivalent to 800 mg acoramidis hydrochloride) taken orally twice daily for 36 months of open label treatment.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Medical Information","CONTACT","1-844-550-2246","medinfo@bridgebio.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":20},"Washington University in St. Louis","RECRUITING","St Louis","Missouri","63110","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-90.19789,38.62727,{"lat":40,"lon":39},{"type":43,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100646198","phase-4-cardiac-magnetic-resonance-and-echocardiography-study-with-acoramidis-100646198",false,"NCT07695701","Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis","An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","ASCEND-ATTR","Key Inclusion Criteria:\n\n* Participants aged 18 to 80\n* Confirmed diagnosis of ATTR-CM requiring targeted therapy\n* At screening: New York Heart Association (NYHA) Class I\u002FII; estimated glomerular filtration rate (eGFR) ≥40 mL\u002Fmin\u002F1.73m2; left ventricular ejection fraction (LVEF) \\>35%; left ventricular (LV) wall thickness ≥12 mm.\n* Heart failure condition has been clinically stable for at least 6 weeks prior to screening.\n\nKey Exclusion Criteria:\n\n* Current or planned implantation of a cardiac implantable electronic device (eg, pacemaker, implantable cardiac defibrillator).\n* Acute myocardial infarction, acute coronary syndrome or coronary revascularization, or experienced stroke or transient ischemic attack within 90 days prior to screening.\n* Hemodynamic instability.\n* Likely to undergo heart transplantation within 12 months from screening.\n* Confirmed diagnosis of AL amyloidosis at screening.\n* At screening: NYHA Class III\u002FIV; National Amyloidosis Center (NAC) Stage 3.\n* Prior or current treatment with acoramidis.","ALL","18 Years","80 Years",{"count":56,"type":57},150,"ESTIMATED","INTERVENTIONAL",[60],"PHASE4","The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.",[63,64,65,66],"Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)","Amyloidosis","Amyloid Cardiomyopathy","Transthyretin Amyloidosis",[68,69,70,71,72],"amyloidosis","cardiomyopathy","ATTR-CM","Amyloid","TTR","2026-07-27",{"date":75,"type":76},"2026-07-29","ACTUAL",{"date":78,"type":57},"2026-07",{"date":80,"type":57},"2030-11",{"name":5,"class":6},1]